<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371368</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR3662</org_study_id>
    <secondary_id>R01DK072011</secondary_id>
    <nct_id>NCT03371368</nct_id>
  </id_info>
  <brief_title>Metabolism and Bariatric Surgery Study</brief_title>
  <official_title>Metabolic and Endocrine Effects of Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if diet-induced weight loss causes different&#xD;
      changes in hormones that control appetite and glucose control than surgery-induced weight&#xD;
      loss. The overall research plan is a non-randomized prospective study of 3 different weight&#xD;
      loss (WL) interventions and a lean and an obese healthy control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Weight loss (WL) improves obesity-related co-morbidities such as type 2 diabetes mellitus&#xD;
      (DM). Unfortunately, WL through life-style interventions has a high degree of relapse and the&#xD;
      lack of safe, effective and affordable therapies together with an increase in the prevalence&#xD;
      of morbid obesity has led to a rise in bariatric procedures. Clinical trials in patients with&#xD;
      DM show that improvements in glycemia vary between procedures and occur in the following&#xD;
      order: Roux-en-Y gastric bypass (RYGB) &gt; sleeve gastrectomy (SG) &gt; laparoscopic adjustable&#xD;
      gastric banding (LAGB) &gt; medical/life-style therapy. This order mirrors the amount of WL with&#xD;
      each intervention and is a major driver of glycemic improvement. The investigators have shown&#xD;
      profound changes unique to RYGB and SG in levels of hormones that make up the &quot;gut-brain&quot; and&#xD;
      &quot;enteroinsular&quot; axes. The association of some of these hormones with insulin sensitivity (IS)&#xD;
      and glycemia, independent of WL strongly suggests that glycemic improvements after surgery&#xD;
      occur in part through pathways that are distinct from just calorie restriction. This study&#xD;
      builds on results showing that levels of fibroblast growth factor 19 (FGF19), a protein&#xD;
      secreted by intestinal cells, are increased after RYGB and SG but not after low calorie diet&#xD;
      (LCD). This difference may affect hormones that control the stress response to weight loss.&#xD;
      The investigators will explore differences in hormones of the gut that affect appetite, body&#xD;
      weight, and stress response in healthy lean and obese individuals. Obese individuals will&#xD;
      also be studied before and after 15% body weight loss induced by LCD, RYGB or SG, and again&#xD;
      at 1 year after study enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine free cortisol level</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>A linear mixed effects model will be used to compare the cortisol changes between the LCD and the surgery groups. Specifically, cortisol change will be modeled as longitudinal outcome, and the main predictors are time and treatment group, and the time-treatment interaction.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Gastric Bypass Diabetic and Non-diabetic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Roux-en-Y gastric bypass surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleeve Gastrectomy Diabetic and Non-diabetic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sleeve gastrectomy surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very Low Calorie Diet Diabetic and Non-diabetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>very low calorie diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-diabetic obese subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-diabetic lean subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y Gastric Bypass (RYGBP)</intervention_name>
    <description>This is a standard RYGBP procedure that would be performed clinically and is not research-specific.</description>
    <arm_group_label>Gastric Bypass Diabetic and Non-diabetic</arm_group_label>
    <other_name>RYGBP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve Gastrectomy (SG)</intervention_name>
    <description>This is a standard SG procedure that would be performed clinically and is not research-specific.</description>
    <arm_group_label>Sleeve Gastrectomy Diabetic and Non-diabetic</arm_group_label>
    <other_name>SG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Very Low Calorie Diet (VLCD)</intervention_name>
    <description>Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian</description>
    <arm_group_label>Very Low Calorie Diet Diabetic and Non-diabetic</arm_group_label>
    <other_name>VLCD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men and women Ages 18-65 Years Old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Altered Sleep-wake Cycle&#xD;
&#xD;
          2. Type 1 or 2 Diabetes&#xD;
&#xD;
          3. Previous Bariatric Surgery&#xD;
&#xD;
          4. Lactose Intolerance&#xD;
&#xD;
          5. Any Special Diet restrictions.&#xD;
&#xD;
          6. Use of medications that may affect body weight at screening or during a 3-month period&#xD;
             prior.&#xD;
&#xD;
          7. Untreated thyroid disease&#xD;
&#xD;
          8. Other medical conditions like Cushing's, acromegaly, Hearth failure, Crohn's disease,&#xD;
             etc.&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
         10. Tobacco or opioid use&#xD;
&#xD;
         11. Alcohol dependence&#xD;
&#xD;
         12. &gt; 3% weight change over the 3month period prior to screening&#xD;
&#xD;
         13. Unwillingness to maintain current level of physical activity over duration of study&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Korner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Korner, MD, PhD</last_name>
    <phone>(212) 305-3725</phone>
    <email>jk181@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerardo Febres, MD</last_name>
    <phone>212-342-0281</phone>
    <email>gjf41@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Korner, M.D, PhD</last_name>
      <phone>212-305-3725</phone>
      <email>jk181@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Judith Korner</investigator_full_name>
    <investigator_title>Professor of Medicine at the Columbia University Medical Center</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Gastric Bypass</keyword>
  <keyword>Sleeve Gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

